SCM
DGX icon

Saba Capital Management’s Quest Diagnostics DGX Stock Holding History

Saba Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-501,800
Closed -$26.9M – 221
2013
Q4 		$26.9M Buy
+501,800
New +$29.8M 1.56% 18
2013
Q3 		– Sell
-234,700
Closed -$14.2M – 164
2013
Q2 		$14.2M Buy
+234,700
New +$14M 1.76% 18

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Saba Capital Management's DGX Position: Q1 2015 in Review

Saba Capital Management sold out of Quest Diagnostics (DGX) in Q1 2015, closing a stake of 95,250 shares — an estimated $6.39M sold.

Saba Capital Management first reported a position in DGX in Q4 2013 and held it in 5 quarters. The position peaked at $6.96M in Q2 2014. 553 funds tracked by Wall St. Rank hold DGX as of Q1 2015.

  • Saba Capital Management reported no remaining Quest Diagnostics position as of Q1 2015 after selling out during the quarter.
  • Saba Capital Management sold 95,250 Quest Diagnostics shares in Q1 2015, an estimated $6.39M.
  • Saba Capital Management first reported a position in Quest Diagnostics in Q4 2013 and held it in 5 quarters.
  • Saba Capital Management's Quest Diagnostics position peaked at $6.96M in Q2 2014.
  • 553 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2015.

Based on Saba Capital Management's 13F filing for Q1 2015, filed 15 May 2015.